Needham & Company LLC Reiterates Buy Rating for Artivion (NYSE:AORT)

Artivion (NYSE:AORT)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They currently have a $34.00 price target on the stock. Needham & Company LLC’s price objective suggests a potential upside of 8.80% from the stock’s previous close.

AORT has been the topic of several other research reports. JMP Securities reiterated a “market outperform” rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Oppenheimer upped their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion presently has a consensus rating of “Buy” and an average price target of $31.80.

Artivion Trading Up 0.7 %

Artivion stock opened at $31.25 on Tuesday. Artivion has a one year low of $16.48 and a one year high of $32.33. The company’s fifty day moving average price is $29.40 and its two-hundred day moving average price is $27.41. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -1,562.55 and a beta of 1.74.

Insiders Place Their Bets

In other Artivion news, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the sale, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. The trade was a 3.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the completion of the transaction, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. The trade was a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,017 shares of company stock worth $600,007. 8.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AORT. Quarry LP increased its position in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares in the last quarter. R Squared Ltd acquired a new position in Artivion in the fourth quarter valued at about $39,000. GAMMA Investing LLC grew its stake in Artivion by 21.8% during the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock worth $79,000 after buying an additional 497 shares during the last quarter. KBC Group NV increased its holdings in shares of Artivion by 80.4% during the fourth quarter. KBC Group NV now owns 2,813 shares of the company’s stock worth $80,000 after buying an additional 1,254 shares in the last quarter. Finally, RiverPark Advisors LLC raised its stake in shares of Artivion by 151.6% in the third quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock valued at $143,000 after acquiring an additional 3,246 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.